Quince therapeutics announces frontiers in neurology publication of long-term safety of erydex in pediatric patients with ataxia-telangiectasia

South san francisco, calif.--(business wire)---- $qncx #biotech--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the online publication of safety data from patients with ataxia-telangiectasia (a-t) treated with erydex for a minimum of 24 months in frontiers in neurology. “a-t is a rare pediatric disease with unmet medical need and no approved therapeutic treatment. this post-hoc a.
QNCX Ratings Summary
QNCX Quant Ranking